Abstract:Endometrial cancer is primarily treated with surgery. Adjuvant treatment strategies for endometrial cancer, such as external beam pelvic radiotherapy, vaginal brachytherapy, chemotherapy, and combined chemotherapy and radiotherapy, have been studied in several randomized trials. Adjuvant treatment is currently based on the presence of clinico-pathological risk factors. Low-risk disease is adequately managed with surgery alone. In high-intermediate risk endometrial cancer, adjuvant vaginal brachytherapy is recommended to maximize local control, with only mild side effects and without impact on quality of life. For high-risk endometrial cancer, recent large randomized trials support the use of pelvic radiotherapy, especially in stage I–II endometrial cancer with risk factors. For women with serous cancers and those with stage III disease, chemoradiation increased both recurrence-free and overall survival, while GOG-258 showed similar recurrence-free survival compared with six cycles of chemotherapy alone, but with better pelvic and para-aortic nodal control with combined chemotherapy and radiotherapy. Recent molecular studies, most notably the work from The Cancer Genome Atlas (TCGA) project, have shown that four endometrial cancer molecular classes can be distinguished; POLE ultra-mutated, microsatellite instable hypermutated, copy-number-low, and copy-number-high. Subsequent studies, using surrogate markers to identify groups analogous to TCGA sub-classes, showed that all four endometrial cancer sub-types are found across all stages, histological types, and grades. Moreover, the molecular sub-groups have proved to have a stronger prognostic impact than histo-pathological tumor characteristics. This introduces an new era of molecular classification based diagnostics and treatment approaches. Integration of the molecular factors and new therapeutic targets will lead to molecular-integrated adjuvant treatment including targeted treatments, which are the rationale of new and ongoing trials. This review presents an overview of current adjuvant treatment strategies in endometrial cancer, highlights the development and evaluation of a molecular-integrated risk profile, and briefly discusses ongoing developments in targeted treatment.

Molecular Targeted Therapy of Gynecological Malignant Tumors: the Development and Challenge, from Laboratory to Clinic

New Developments in Molecular Targeted Therapy of Ovarian Cancer.

New windows of surgical opportunity for gynecological cancers in the era of targeted therapies

Recent Therapeutic Advances in Gynecologic Oncology: A Review

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Molecular targeted therapy for the treatment of gastric cancer

Targeted therapy for gynecologic cancers: Toward the era of precision medicine

Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer

Targeted Therapy for Intractable Cancer on the Basis of Molecular Profiles: an Open-Label, Phase II Basket Trial (long March Pathway)

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Molecular targeted therapy for anticancer treatment

Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities

Molecular targeting therapy for gastric cancer

Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway

Metastatic gynecologic malignancies: advances in treatment and management

Molecular basis and clinical application of targeted therapy in oncology

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Combined modality including novel sensitizers in gynecological cancers